Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

Organon and Pharmacopeia Ally for Discovery, Development, and Commercilization

  • Pharmacopeia and Organon entered into a alliance to discover, develop, and commercialize therapeutic products across a range of therapeutic indications, including neuroscience and immunology.

    Pharmacopeia will receive an upfront payment of $15 million and additional payments in funding over the five-year term of the research work. Development will be primarily handled by Organon. Additionally, Pharmacopeia will receive milestone payments on any succesful candidate that Organon advances through clinical development, and up to double-digit royalties based on commercialization.

    Pharmacopeia retains the option to co-develop and co-commercialize therapeutic candidates discovered through the alliance. Organon will hold exclusive rights on any compound that Pharmocopeia choses to not exercise this option.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »